Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GRAIL, Inc. - Common Stock (NQ:GRAL)

58.20 -13.48 (-18.81%)
Streaming Delayed Price Updated: 10:50 AM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GRAIL, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint ↗
GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify more cancers through... 
Via MarketBeat
News headline image
Grail's Slump Enters Week 10. Is There Any End in Sight? ↗
Despite a disappointing trial result, there's still a case for buying the stock, with a near-term catalyst on the horizon. 
Via The Motley Fool
News headline image
This Beaten-Down Growth Stock Could Soar 30%, According to Wall Street ↗
Grail's Galleri trial was disappointing, but it isn't down for the count yet. 
Via The Motley Fool
News headline image
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead ↗
GRAIL (NASDAQ:GRAL) said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who... 
Via MarketBeat
GRAIL INC (NASDAQ:GRAL) Stock Falls After-Hours Despite Q1 Beat and Galleri Test Volume Surge ↗
Via Chartmill
GRAIL INC (NASDAQ:GRAL) Plummets 47% Despite Narrower-Than-Expected Q4 Loss ↗
Via Chartmill
News headline image
Here's Why Grail Shares Popped Higher This Week ↗
The company recently reported better-than-expected results, and investors are hoping for more positive news at the end of the month. 
Via The Motley Fool
News headline image
Grail (GRAL) Q1 2026 Earnings Transcript ↗
Grail (GRAL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Better Healthcare Stock to Own in a Recession: Defensive or Growth? ↗
The answer to the question might surprise many investors. It pays to be open-minded about risk. 
Via The Motley Fool
Topics Economy Energy
News headline image
Here's Why Grail Stock Soared Higher This Week ↗
Wall Street continues to warm to the investment proposition for this high-risk and high-reward stock. 
Via The Motley Fool
Topics Earnings
News headline image
This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month ↗
GRAIL, Inc. develops blood-based cancer detection technologies for healthcare providers and individuals seeking early screening solutions. 
Via The Motley Fool
News headline image
Here's Why Grail Shares Crushed the Market This Week ↗
The company's stock received a favorable assessment from a Wall Street analyst this week. 
Via The Motley Fool
News headline image
Here's Why Grail Shares Crashed in February and Why it Could Be a Buying Opportunity ↗
The multi-cancer early detection (MCED) company delivered some extremely bad news to investors in February, but the stock may attract risk tolerant investors now. 
Via The Motley Fool
News headline image
Here's Why Grail Stock Bounced Back 16% Today ↗
The market took a more positive view on the company's prospects today, and there's still an opportunity, however small, for the Galleri trial to prove out. 
Via The Motley Fool
Topics Earnings
News headline image
Why Grail Shares Are Plummeting ↗
A large clinical trial of the company's cancer screening test did not produce the desired result. 
Via The Motley Fool
News headline image
Here's Why Grail Stock Slumped Again Today ↗
The company continues to come under pressure after a very disappointing trial result. 
Via The Motley Fool
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
Via The Motley Fool
Topics Regulatory Compliance
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Here's Why Grail Stock Crashed 50% Today ↗
The top-line results from its landmark trial were not good, but there's more data to come, and it might prove more favorable for investors. 
Via The Motley Fool
Top movers in Friday's session ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗
Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating. 
Via Stocktwits
News headline image
Why Grail Stock Is Sinking Friday ↗
GRAIL (NASDAQ: GRAL) shares plunged after the NHS-Galleri trial failed to meet its primary endpoint. Explore the trial results. 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
GRAL Stock Slumps After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses ↗
The trial did not show a statistically significant reduction in Stage III-IV cancer diagnoses, the company said. 
Via Stocktwits
Topics Artificial Intelligence Death
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Here's Why This Exciting Healthcare Stock Popped 13% Today ↗
Investors are getting excited by the prospects for Grail's Galleri test in 2026. 
Via The Motley Fool
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an... 
Via MarketMinute
News headline image
Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025 ↗
Via MarketBeat
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.